VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors

被引:157
作者
Dasgupta, Suryasarathi
Repesse, Yohann
Bayry, Jagadeesh
Navarrete, Ana-Maria
Wootla, Bharath
Delignat, Sandrine
Irinopoulou, Theano
Kamate, Caroline
Saint-Remy, Jean-Marie
Jacquemin, Marc
Lenting, Peter J.
Borel-Derlon, Annie
Kaveri, Srinivas V.
Lacroix-Desmazes, Sebastien [1 ]
机构
[1] Inst Biomed Cordeliers, INSERM UMRS 681, 15 Rue Ecole Med, F-75005 Paris, France
[2] Univ Paris 06, Inst Cordeliers, IFR 58, F-75252 Paris 05, France
[3] Inst Fer Moulin, IFR 83, Paris, France
[4] Univ Caen, Hematol Lab, EA 3212, F-14032 Caen, France
[5] INSERM, U536, U706, Paris, France
[6] Univ Utrecht, Dept Hematol, Lab Thrombosis & Haemostasis, NL-3508 TC Utrecht, Netherlands
[7] Univ Louvain, Ctr Mol & Vasc Biol, Louvain, Belgium
关键词
D O I
10.1182/blood-2006-05-022756
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Von Willebrand factor (VWF) is a chaperone molecule for procoagulant factor Vill (FVIII). its role in the reduction of the immunogenicity of therapeutic FVIII in patients with hemophilia A has been evoked but lacks clear cellular and molecular rationale. Here, we demonstrate that VWF protects FVIII from being endocytosed by human dendritic cells (DCs) and subsequently presented to FVIII-specific T cells. The immunoprotective effect of VWF requires a physical interaction with FVIII because the endocytosis of FVIII was significantly restored on hindering the formation of the VWF-FVIII complex. Interestingly, VWF had no direct inhibitory effect either on the ability of DCs to present antigenic peptides or on the activation potency of CD4(+) T cells. We thus propose that VWIF may reduce the immunogenicity of FVIII by preventing, upstream from the activation of immune effectors, the entry of FVIII in professional antigenpresenting cells.
引用
收藏
页码:610 / 612
页数:3
相关论文
共 18 条
[1]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[2]  
Behrmann M, 2002, THROMB HAEMOSTASIS, V88, P221
[3]   LDL receptor cooperates with LDL receptor-related protein in regulating plasma levels of coagulation factor VIII in vivo [J].
Bovenschen, N ;
Mertens, K ;
Hu, LH ;
Havekes, LM ;
van Vlijmen, BJM .
BLOOD, 2005, 106 (03) :906-912
[4]   Elevated plasma factor VIII in a mouse model of low-density lipoprotein receptor-related protein deficiency [J].
Bovenschen, N ;
Herz, J ;
Grimbergen, JM ;
Lenting, PJ ;
Havekes, LM ;
Mertens, K ;
van Viijmen, BJM .
BLOOD, 2003, 101 (10) :3933-3939
[5]  
Castaman G, 2003, HAEMATOLOGICA, V88, P94
[6]   Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A [J].
Goudemand, J ;
Rothschild, C ;
Demiguel, V ;
Vinciguerrat, C ;
Lambert, T ;
Chambost, H ;
Borel-Derlon, A ;
Claeyssens, S ;
Laurian, Y ;
Calvez, T .
BLOOD, 2006, 107 (01) :46-51
[7]   A CD91-positive subset of CD11c+ blood dendritic cells:: Characterization of the APC that functions to enhance adaptive immune responses against CD91-targeted antigens [J].
Hart, JP ;
Gunn, MD ;
Pizzo, SV .
JOURNAL OF IMMUNOLOGY, 2004, 172 (01) :70-78
[8]   CD4+ T-cell clones specific for wild-type factor VIII:: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A [J].
Jacquemin, M ;
Vantomme, V ;
Buhot, C ;
Lavend'homme, R ;
Burny, W ;
Demotte, N ;
Chaux, P ;
Peerlinck, K ;
Vermylen, J ;
Maillere, B ;
van der Bruggen, P ;
Saint-Remy, JM .
BLOOD, 2003, 101 (04) :1351-1358
[9]  
Kaufman RJ, 1999, THROMB HAEMOSTASIS, V82, P201
[10]   An experimental model to study the in vivo survival of von Willebrand factor -: Basic aspects and application to the R1205H mutation [J].
Lenting, PJ ;
Westein, E ;
Terraube, V ;
Ribba, AS ;
Huizinga, EG ;
Meyer, D ;
de Groot, PG ;
Denis, CV .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (13) :12102-12109